home Search results for 'Eat'
Apparatus

Biyze For The Treatment Of Chronic Lymphocytic Leukaemia And Marginal Zone Lymphoma

Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.

Medical

New Treatment For Uroepithelial Carcinoma Receives Fda Fast Track Designation With Encouraging Initial Results

The FDA granted Fast Track designation to a new drug, IK-175, in combination with nabumab for the treatment of advanced uroepithelial carcinoma, after preliminary trial data showed encouraging and durable anti-tumor activity with a favorable safety profile.